Table 1 Patients characteristics
STING study | ||
Number of patients | N = 626 | |
Sex | Male Female | 336 53.7% 290 46.3% |
Age | Median (range) | Med = 64 (19; 90) |
Cancer type | Colorectal cancer Non-small cell lung cancer Thyroid cancer Breast cancer Head and neck cancer Prostate cancer Others | 58 9.3% 10316.4% 23 3.7% 12619.8% 304.8% 18830.0% 9816% |
Type of treatment | Tyrosine kinase inhibitor Monoclonal antibody Hormonal therapy | 17628.1% 13822.0% 31249.9% |
PS (at ctDNA) | 0 1 2 Missing values | 22636.1% 28946.2% 457.2% 6610.5% |
BIP study | ||
Number of patients | N = 437 | |
Sex | Male Female | 155 35.5% 282 64.5% |
Age | Median (range) | Med = 66 (21 ; 87) |
Cancer type | Colorectal cancer Non-small cell lung cancer Breast cancer Prostate cancer | 62 14.2% 14 3.2% 25157.4% 1102.5% |
Type of treatment | Tyrosine kinase inhibitor Monoclonal antibody Hormonal therapy | 143.2% 6214.2% 36182.6% |
ECOG Performance Status (at ctDNA assesment) | 0 1 2 | 17,039% 21,850% 4911% |